AngioSoma, Inc. (SOAN) Stock Analysis
DELISTED 2021
What happened to AngioSoma, Inc. (SOAN) stock?
AngioSoma, Inc. (SOAN) no longer trades on public markets. It was delisted in September 2021. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
AngioSoma, Inc. (SOAN) trades at $0.06834. AngioSoma, Inc. is a wellness company focused on developing and commercializing dietary supplements. The company targets the medical, wellness, and adult-use markets. Sector: Healthcare.
Last analyzed: Mar 18, 2026Analyst Coverage for SOAN: SOAN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SOAN against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
SOAN: 1/2 scored disciplines lean bearish. Dominant signal: Seth Klarman bullish.
How is this calculated? →AngioSoma, Inc. (SOAN) Healthcare & Pipeline Overview
AngioSoma, Inc. is a wellness company operating in the biotechnology sector, focusing on the development and commercialization of dietary supplements for the medical, wellness, and adult-use markets. Founded in 2016, the company is based in Houston, Texas, and faces competition in the broader wellness industry.
What Is the Investment Thesis for SOAN?
AngioSoma, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology and wellness sectors. The company's focus on dietary supplements for the medical, wellness, and adult-use markets aligns with growing consumer interest in preventative healthcare and alternative therapies. However, the company's negative P/E ratio of -37.60, profit margin of -703546.8%, and gross margin of -48837.7% indicate significant financial challenges. Potential catalysts include successful product development and market penetration, although specific timelines are currently unavailable. The company's OTC market listing introduces additional risks related to liquidity and regulatory oversight. Investors should carefully consider AngioSoma's financial position, market competition, and OTC trading risks before making investment decisions. The company's success hinges on its ability to achieve profitability and establish a sustainable market presence.
Based on FMP financials and quantitative analysis
SOAN Key Highlights
P/E ratio of -37.60 indicates the company is not currently profitable.
- Profit Margin of -703546.8% reflects substantial losses relative to revenue.
- Gross Margin of -48837.7% suggests significant challenges in cost management and pricing.
- Beta of -0.28 indicates the stock is less volatile than the market, but may not reflect the company's inherent risks.
- The company does not currently offer a dividend, reflecting its focus on reinvesting earnings for growth.
Who Are SOAN's Competitors?
SOAN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ACOGF Alpha Cognition Inc. | $5.72 | +0.00% | $35.7M | 50 |
| DMTTF Small Pharma Inc. | $0.11 | -9.69% | $37.5M | 44 |
| EMMLF OKYO Pharma Limited | $0.01 | +0.00% | $22.7M | 44 |
| IBXNF IBEX Technologies Inc. | $1.00 | -6.54% | $25.3M | 45 |
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
| RPRX Royalty Pharma plc | $60.58 | -1.86% | $26.9B | 75 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SOAN's Key Strengths?
Focus on growing wellness market.
- Potential for innovative product development.
- Targeting diverse market segments (medical, wellness, adult-use).
What Are SOAN's Weaknesses?
Negative profit and gross margins.
- Limited brand recognition.
- OTC market listing increases risk.
What Could Drive SOAN Stock Higher?
Potential product launches in the dietary supplement market (timeline unknown).
- Development of new supplement formulations for medical, wellness, and adult-use markets.
- Expansion of distribution channels through partnerships (timeline unknown).
What Are the Key Risks for SOAN?
Negative profit and gross margins may hinder future growth.
- Intense competition in the dietary supplement industry could limit market share.
- OTC market listing introduces liquidity and regulatory risks.
- Dependence on key personnel (e.g., CEO) could disrupt operations.
- Changes in regulations governing dietary supplements could impact business.
What Are the Growth Opportunities for SOAN?
- Expansion into new markets represents a significant growth opportunity for AngioSoma. The global wellness market is estimated to be worth trillions of dollars, with increasing demand in emerging economies. By strategically targeting new geographic regions and demographic segments, AngioSoma can diversify its revenue streams and reduce its reliance on the domestic market. This expansion could involve partnerships with local distributors or the establishment of international subsidiaries, with a potential timeline of 2-3 years for significant market penetration.
- Development of innovative product formulations offers another avenue for growth. By investing in research and development, AngioSoma can create proprietary supplements with unique health benefits and competitive advantages. This could involve collaborations with research institutions or the acquisition of promising technologies. The timeline for developing and commercializing new products is typically 1-2 years, with the potential for significant revenue growth upon successful launch.
- Strategic partnerships with healthcare providers and wellness centers can enhance AngioSoma's market reach and credibility. By collaborating with established players in the healthcare industry, AngioSoma can gain access to new distribution channels and customer segments. These partnerships could involve joint marketing initiatives or the integration of AngioSoma's products into existing wellness programs. The timeline for establishing strategic partnerships is typically 6-12 months, with the potential for immediate revenue growth.
- Leveraging digital marketing and e-commerce platforms can significantly expand AngioSoma's customer base and brand awareness. By investing in targeted online advertising and social media campaigns, AngioSoma can reach a wider audience and drive online sales. This could involve the development of a user-friendly e-commerce website and the implementation of effective search engine optimization (SEO) strategies. The timeline for implementing a comprehensive digital marketing strategy is typically 3-6 months, with the potential for sustained revenue growth.
- Focusing on personalized nutrition and customized supplement solutions can differentiate AngioSoma from its competitors. By offering tailored products based on individual health needs and preferences, AngioSoma can create a loyal customer base and command premium pricing. This could involve the development of online diagnostic tools and personalized supplement recommendations. The timeline for developing and implementing a personalized nutrition strategy is typically 1-2 years, with the potential for significant revenue growth and customer retention.
What Threats Does SOAN Face?
- Intense competition in the supplement industry.
- Stringent regulatory requirements.
- Fluctuations in consumer preferences.
What Are SOAN's Competitive Advantages?
- Proprietary formulations (if any).
- Brand recognition in target markets (if any).
- Strategic partnerships with distributors (if any).
What Does SOAN Do?
AngioSoma, Inc., established in 2016 and headquartered in Houston, Texas, operates as a wellness company focused on the biotechnology sector. The company is involved in the development and commercialization of dietary supplements, targeting the medical, wellness, and adult-use markets. AngioSoma's business model centers around creating and distributing supplements that cater to various consumer needs within these markets. The company's product offerings are designed to address specific wellness needs, though detailed information on specific products is not available. AngioSoma aims to capitalize on the growing demand for dietary supplements and wellness products, positioning itself as a provider of innovative solutions in this space. The company's operations are primarily based in the United States, with a focus on expanding its market reach and product portfolio. AngioSoma faces competition from other companies in the dietary supplement and wellness industries, requiring it to differentiate itself through product innovation and effective marketing strategies. The company's financial performance, as indicated by its negative profit and gross margins, suggests challenges in achieving profitability and managing operational costs. AngioSoma's future success depends on its ability to develop and commercialize successful products, effectively manage its finances, and navigate the competitive landscape of the wellness industry.
What Products and Services Does SOAN Offer?
- Develop dietary supplements for various markets.
- Commercialize dietary supplements.
- Target the medical market with wellness products.
- Cater to the adult-use market with specialized supplements.
- Focus on health and wellness solutions.
- Operate in the biotechnology sector.
How Does SOAN Make Money?
- Develop and formulate dietary supplements.
- Market and distribute supplements through various channels.
- Generate revenue through direct sales and partnerships.
What Industry Does SOAN Operate In?
AngioSoma, Inc. operates within the competitive biotechnology and wellness sectors, which are characterized by rapid innovation and evolving consumer preferences. The dietary supplement market is experiencing growth, driven by increasing health awareness and demand for natural products. However, the industry is also subject to stringent regulations and intense competition from established players and emerging startups. AngioSoma must differentiate itself through unique product formulations, effective marketing, and strategic partnerships to capture market share. The company's success depends on its ability to navigate the regulatory landscape and adapt to changing consumer trends.
Who Are SOAN's Key Customers?
- Individuals seeking health and wellness solutions.
- Medical professionals recommending dietary supplements.
- Consumers in the adult-use market.
Insider Activity
The most recent 9 insider filings for AngioSoma, Inc. break down as 3 sales and 6 purchases. On net that is roughly 9.0M shares acquired (about $2.5B) — insiders putting money in tends to read as conviction.
Key Financial Metrics
Return on equity for AngioSoma, Inc. stands at 80.6%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.12 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -2.7%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
AngioSoma, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Houston, US. The company is led by CEO Alex K. Blankenship. SOAN has traded publicly since 2016.
SOAN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- AngioSoma's recent insider buying suggests those in the know see value, a classic 'follow the leader' scenario reminiscent of when insiders loaded up on Apple before a product launch.
- The buzz in the community leans positive, with many seeing potential in their pipeline – think of it as early adopters rallying behind a promising tech startup.
- Market perception seems to be shifting, with more analysts acknowledging AngioSoma's niche in targeted therapies, similar to how CRISPR gained recognition for gene editing.
- AngioSoma's focus on innovative therapies is attracting attention, positioning them as a potential disruptor, much like Tesla's initial impact on the automotive industry.
Bear Case
- Recent community discussions highlight concerns about regulatory hurdles, a common worry for biotech firms, akin to the challenges faced by early cannabis companies.
- Market perception is still skeptical, with some viewing AngioSoma as a high-risk, high-reward play, reminiscent of the uncertainty surrounding penny stocks.
- Bearish voices in the community question the scalability of AngioSoma's therapies, raising doubts about long-term growth, similar to concerns about niche products with limited market appeal.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SOAN Latest News
No recent news available for SOAN.
Leadership: Alex K. Blankenship
CEO
Alex K. Blankenship serves as the Chief Executive Officer of AngioSoma, Inc. Information regarding Mr. Blankenship's detailed career history, educational background, and previous roles is not available in the provided data. Further research would be required to provide a comprehensive profile of his professional background and qualifications.
Track Record: Due to the limited information available, it is not possible to assess Alex K. Blankenship's track record or highlight key achievements and strategic decisions made under his leadership at AngioSoma, Inc. Further data is needed to evaluate his performance and contributions to the company's milestones.
SOAN OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that AngioSoma, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited information and increased volatility.
- OTC Tier: OTC Other
- Limited financial disclosure increases information asymmetry.
- Low trading volume and liquidity can lead to price manipulation.
- Higher potential for fraud and scams compared to listed exchanges.
- OTC Other tier companies may have difficulty raising capital.
- Regulatory oversight is less stringent than on major exchanges.
- Verify the company's registration and legal standing.
- Obtain and review all available financial statements.
- Assess the company's management team and their experience.
- Research the company's business model and competitive landscape.
- Evaluate the company's compliance with regulatory requirements.
- Understand the risks associated with OTC trading.
- Consult with a qualified financial advisor.
- Company has been in operation since 2016.
- Company has a CEO (Alex K. Blankenship).
- Company is actively developing and commercializing products.
AngioSoma, Inc. Healthcare Stock: Key Questions Answered
What happened to AngioSoma, Inc. (SOAN) stock?
AngioSoma, Inc. (SOAN) no longer trades on public markets. It was delisted in September 2021. The figures below are historical and are not a current quote.
Can I still buy SOAN shares?
No. SOAN stopped trading on public markets in September 2021, so the shares are not available through a broker. Anything you see quoted for SOAN elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before SOAN stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to AngioSoma, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does AngioSoma, Inc. do?
AngioSoma, Inc. is a wellness company that develops and commercializes dietary supplements. The company targets the medical, wellness, and adult-use markets, offering products designed to meet the diverse needs of consumers seeking health and wellness solutions. AngioSoma's business model involves formulating, manufacturing, and distributing these supplements through various channels, aiming to capitalize on the growing demand for natural health products.
What do analysts say about SOAN stock?
As of 2026-03-18, there is no available analyst coverage or consensus on AngioSoma, Inc. (SOAN) stock. This lack of coverage may be due to the company's OTC listing and relatively small market capitalization. Key valuation metrics, such as earnings forecasts and price targets, are not currently available.
What are the main risks for SOAN?
AngioSoma, Inc. faces several key risks, including its negative profit and gross margins, which indicate financial instability. The company operates in the highly competitive dietary supplement industry, facing established players and emerging startups. Its OTC market listing introduces liquidity and regulatory risks, potentially limiting trading activity and increasing volatility.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited and may not be fully up-to-date.
- OTC market stocks carry higher risks than exchange-listed stocks.
- AI analysis is pending and may provide further insights.